Preclinical antitumor activity of batracylin (NSC 320846).

Abstract

Batracylin (NSC 320846, BAY H 2049), given ip on days 2 and 9 at a dose 400 mg/kg, inhibited tumor growth completely in 80-100% of mice with early-stage colon adenocarcinoma 38. Therapeutic efficacy against this subcutaneously implanted tumor was retained upon oral administration of Batracylin although, compared to ip treatment, larger doses were required. Batracylin also caused regression of advanced (400 mg) colon 38 tumors. Only modest activity was observed for this compound against P388 leukemia, but P388 sublines with acquired resistance to either adriamycin or cisplatin demonstrated collateral sensitivity. Batracylin currently is undergoing toxicological evaluation by NCI prior to clinical trials.

• Authors: J Plowman, K D Paull, G Atassi, S D Harrison Jr, D J Dykes, H J Kabbe, V L Narayanan, O C Yoder
• Journal: Investigational new drugs (Invest New Drugs) Vol. 6 Issue 3 Pg. 147-53 (Sep 1988) ISSN: 0167-6997 [Print] United States
• PMID: 3192381 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Quinazolines
• batracylin

Topics

• Adenocarcinoma (drug therapy)
• Administration, Oral
• Animals
• Antineoplastic Agents (therapeutic use)
• Colonic Neoplasms (drug therapy)
• Drug Evaluation, Preclinical
• Injections, Intraperitoneal
• Leukemia P388 (drug therapy)
• Leukemia, Experimental (drug therapy)
• Mice
• Mice, Inbred Strains
• Quinazolines (administration & dosage, therapeutic use)
• Tumor Cells, Cultured (drug effects)